HCA Healthcare, Inc. (HCA) Stock Analysis and Metrics

HCA Healthcare

NYSE: HCA

$371.36 ▼ -14.38 (-3.73%)

At close: Jul 17, 2026 · 3:59 PM UTC

Financial Ratios

Market Cap87.94 Bn

P/E11.25

P/S1.15

Div. Yield0.01

ROIC (Qtr)-0.03

Total Debt (Qtr)48.02 Bn

Revenue Growth (1y) (Qtr)4.30

Add ratio to table…

About

HCA Healthcare, Inc. is a leading health care services provider in the United States, operating a vast network of hospitals and outpatient facilities. The company delivers a comprehensive range of medical services, including general acute care, behavioral health, and rehabilitation, alongside outpatient services such as ambulatory surgery centers, emergency care, and diagnostic imaging. With 190 hospitals and 152 freestanding outpatient centers across 19 states and England as of December 31, 2025, HCA Healthcare focuses on delivering high-quality, cost-effective care through a blend of inpatient and outpatient offerings.

HCA Healthcare generates revenue primarily through patient services, reimbursed by government programs, private insurers, and direct payments. In 2025, the company reported $75.6 billion in revenues, with the largest share coming from managed care and other private insurers, accounting for 48.9% of total revenues. Medicare and Medicaid contributed 14.9% and 7.8%, respectively, while managed Medicare and Medicaid programs added 17.8% and 4.9%. The company also serves uninsured patients, who represented 3.2% of revenues, and international patients, contributing 2.5%. Reimbursement rates vary by payer, with government programs typically offering lower rates than private insurers, and the company negotiates contracts with managed care plans to secure favorable terms.

The company operates through distinct service lines that form its core operational segments.

• General Acute Care Hospitals: This segment includes 179 hospitals with 50,436 licensed beds, providing a full spectrum of inpatient and outpatient services. These hospitals offer medical and surgical specialties such as cardiology, oncology, orthopedics, and obstetrics, along with diagnostic, emergency, and ancillary services. They also operate outpatient facilities, including surgery centers, urgent care clinics, and diagnostic centers, to create integrated care networks in local communities.

• Behavioral Hospitals: HCA Healthcare operates seven behavioral hospitals with 714 licensed beds, delivering mental health and substance abuse treatment. Services include inpatient psychiatric care, partial hospitalization, and outpatient programs for children, adolescents, and adults. These facilities address a critical need for specialized mental health services within the broader health care system.

• Rehabilitation Hospitals: The company owns four rehabilitation hospitals, focusing on intensive physical and occupational therapy for patients recovering from strokes, spinal cord injuries, and other debilitating conditions. These facilities provide specialized care to restore functional independence and improve patient outcomes.

• Outpatient Services: This segment encompasses 121 freestanding ambulatory surgery centers and 31 endoscopy centers, offering cost-effective alternatives to hospital-based procedures. These centers perform a wide range of outpatient surgeries and diagnostic services, often in partnership with physicians, and are designed to enhance accessibility and efficiency for patients and providers.

HCA Healthcare holds a dominant position in the U. S. health care industry, ranking as one of the largest hospital operators by revenue and facility count. The company competes with other for-profit hospital chains, such as Tenet Healthcare and Community Health Systems, as well as not-for-profit and government-owned hospitals. Its competitive advantages include a vast network of facilities, economies of scale in purchasing and operations, and a strong focus on clinical quality and patient satisfaction. The company leverages its size to negotiate favorable contracts with suppliers and insurers, while its investment in digital and artificial intelligence capabilities enhances operational efficiency and care coordination. However, HCA Healthcare faces challenges from regulatory pressures, labor shortages, and competition from freestanding specialty providers.

HCA Healthcare serves a diverse customer base, including patients covered by government programs like Medicare and Medicaid, as well as those with private insurance through employers or health exchanges. The company also treats uninsured patients, who often access care through emergency rooms, and international patients seeking specialized medical services. While the filing does not disclose specific customer names, HCA Healthcare’s payer mix reflects broad engagement with managed care organizations, commercial insurers, and government agencies. The company’s facilities are concentrated in high-growth markets, particularly Florida and Texas, where it benefits from strong demand for health care services.

Investment Thesis

▲ Bull case

HCA’s network expansion is creating a durable growth engine that the market is under‑pricing. The company increased its site‑of‑care footprint by over 4%, added nearly 1% more hospital beds through capital projects, and expanded emergency room capacity by 4% in the quarter. These investments are backed by a $5.5‑$6 billion pipeline of approved projects slated to come online over the next 24‑30 months, which will lift inpatient and outpatient volumes without requiring new greenfield builds. As occupancy remains high, the incremental capacity will translate directly into higher equivalent admissions and revenue per equivalent admission, which already rose 3.1% year‑over‑due to case mix acuity gains. The market’s focus on short‑term volume volatility overlooks this structural capacity uplift that will sustain mid‑single‑digit revenue growth for years.
Supplemental Medicaid payment programs are proving to be a more reliable and sizable earnings contributor than currently modeled. In Q1 HCA captured a $200 million net benefit, $120 million above internal expectations, driven by the grandfathered Georgia approval and the reinstatement of the ATLAS program in Texas. Management has raised the full‑year supplemental payment outlook to a decline of only $50‑$250 million versus prior year, excluding any future grandfathered approvals, and noted that Florida’s pending program, if approved, could generate “significant” additional revenue. The market’s guidance assumes a modest headwind from these programs, yet the upside potential from new state approvals and the durability of existing programs provides a cushion that could lift EBITDA margins beyond the current 19.9% level.
Cost‑resiliency initiatives and AI‑driven productivity are beginning to deliver tangible margin improvement that is not yet reflected in consensus estimates. Salaries and benefits as a percentage of revenue improved 30 bps and supply costs improved 20 bps in the quarter, partially offsetting a 90 bps rise in other operating expenses. HCA reaffirmed a $400 million annualized benefit target from its resiliency plan, which includes ambient listening for physicians, nurse handoff programs, and broader digital transformation efforts. As these tools scale across the network, the company expects to reclaim operating leverage lost during the seasonal respiratory dip, driving EBITDA growth ahead of the 2% guidance midpoint. Analysts have not fully priced in the incremental margin expansion from these technology‑enabled efficiencies.
The recent acquisition of The College of Health Care Professions (CHCP) strengthens HCA’s long‑term talent pipeline and supports margin stability through reduced recruitment costs and higher workforce quality. CHCP trains over 8,000 students annually across Texas and online, providing a ready source of skilled allied health professionals for HCA’s urgent care, ambulatory surgery, and freestanding ER sites. By internalizing this training pipeline, HCA can mitigate labor market tightness, lower turnover, and enhance patient satisfaction scores, all of which contribute to better reimbursement rates and lower cost per case. The market treats this as a peripheral news item, yet it addresses a core industry challenge—workforce scarcity—that could improve HCA’s competitive positioning and financial performance over the next three to five years.
Contracting discipline provides a predictable revenue backdrop that reduces earnings volatility. HCA stated it is “pretty much fully contracted at our targeted levels” for 2026 and is already a third of the way through 2027 contract renewals, indicating minimal risk of mid‑term rate resets. This contractual maturity shields the company from sudden payer‑driven revenue swings and allows management to focus on volume and cost execution. Investors who are wary of exchange‑related payer mix shifts overlook the protective effect of a locked‑in contract base, which stabilizes cash flow and supports the company’s aggressive share repurchase program ($1.57 billion in Q1) and dividend policy.

HCA’s network expansion is creating a durable growth engine that the market is under‑pricing. The company increased its site‑of‑care footprint by over 4%, added nearly 1% more hospital beds through capital projects, and expanded emergency room capacity by 4% in the quarter. These investments are backed by a $5.5‑$6 billion pipeline of approved projects slated to come online over the next 24‑30 months, which will lift inpatient and outpatient volumes without requiring new greenfield builds. As occupancy remains high, the incremental capacity will translate directly into higher equivalent admissions and revenue per equivalent admission, which already rose 3.1% year‑over‑due to case mix acuity gains. The market’s focus on short‑term volume volatility overlooks this structural capacity uplift that will sustain mid‑single‑digit revenue growth for years.
Supplemental Medicaid payment programs are proving to be a more reliable and sizable earnings contributor than currently modeled. In Q1 HCA captured a $200 million net benefit, $120 million above internal expectations, driven by the grandfathered Georgia approval and the reinstatement of the ATLAS program in Texas. Management has raised the full‑year supplemental payment outlook to a decline of only $50‑$250 million versus prior year, excluding any future grandfathered approvals, and noted that Florida’s pending program, if approved, could generate “significant” additional revenue. The market’s guidance assumes a modest headwind from these programs, yet the upside potential from new state approvals and the durability of existing programs provides a cushion that could lift EBITDA margins beyond the current 19.9% level.
Cost‑resiliency initiatives and AI‑driven productivity are beginning to deliver tangible margin improvement that is not yet reflected in consensus estimates. Salaries and benefits as a percentage of revenue improved 30 bps and supply costs improved 20 bps in the quarter, partially offsetting a 90 bps rise in other operating expenses. HCA reaffirmed a $400 million annualized benefit target from its resiliency plan, which includes ambient listening for physicians, nurse handoff programs, and broader digital transformation efforts. As these tools scale across the network, the company expects to reclaim operating leverage lost during the seasonal respiratory dip, driving EBITDA growth ahead of the 2% guidance midpoint. Analysts have not fully priced in the incremental margin expansion from these technology‑enabled efficiencies.
The recent acquisition of The College of Health Care Professions (CHCP) strengthens HCA’s long‑term talent pipeline and supports margin stability through reduced recruitment costs and higher workforce quality. CHCP trains over 8,000 students annually across Texas and online, providing a ready source of skilled allied health professionals for HCA’s urgent care, ambulatory surgery, and freestanding ER sites. By internalizing this training pipeline, HCA can mitigate labor market tightness, lower turnover, and enhance patient satisfaction scores, all of which contribute to better reimbursement rates and lower cost per case. The market treats this as a peripheral news item, yet it addresses a core industry challenge—workforce scarcity—that could improve HCA’s competitive positioning and financial performance over the next three to five years.
Contracting discipline provides a predictable revenue backdrop that reduces earnings volatility. HCA stated it is “pretty much fully contracted at our targeted levels” for 2026 and is already a third of the way through 2027 contract renewals, indicating minimal risk of mid‑term rate resets. This contractual maturity shields the company from sudden payer‑driven revenue swings and allows management to focus on volume and cost execution. Investors who are wary of exchange‑related payer mix shifts overlook the protective effect of a locked‑in contract base, which stabilizes cash flow and supports the company’s aggressive share repurchase program ($1.57 billion in Q1) and dividend policy.

▼ Bear case

Exchange‑driven payer mix deterioration remains a material and underappreciated headwind that could erode profitability faster than anticipated. Exchange equivalent admissions fell 15% in the quarter, while uninsured equivalent admissions rose 16%, generating an estimated $150 million EBITDA impact in Q1 and a full‑year guidance range of $600‑$900 million. Management acknowledged that the shift from silver to bronze plans and rising patient cost‑share are increasing patient amounts due, which historically collect at lower rates than traditional managed care. If the exchange attrition accelerates or if Medicaid conversion slowdown persists, the uninsured burden could widen, pressuring bad‑debt reserves and offsetting gains from supplemental payments and cost‑savings initiatives.
Reliance on Medicaid supplemental payment programs introduces earnings volatility that may not be fully captured in current forecasts. While Q1 benefited from a $200 million net boost, the company revised its full‑year supplemental payment outlook to a potential decline of $50‑$250 million versus prior year, excluding any future grandfathered approvals. The sustainability of these programs hinges on state budget decisions and federal approval processes, which are inherently uncertain. A delay or denial of Florida’s pending program, or a rollback of existing programs in Georgia or Texas, could reverse the recent earnings boost and leave HCA more exposed to the underlying volume and payer mix pressures.
Operational challenges in specific markets, exemplified by North Carolina, reveal localized cost pressures that could scale if similar workforce shortages emerge elsewhere. HCA noted it is “a little bit behind our expectations in North Carolina on the bottom line” due to above‑expected demand requiring costly temporary labor to overcome a workforce deficit. If other regions experience comparable demand surges coupled with labor scarcity, the incremental cost burden could erode the modest salary and benefits margin improvements seen company‑wide. The market may view these as isolated issues, yet they signal a potential systemic risk to cost control in tight labor markets.
Denials and underpayments, particularly within Medicare Advantage, remain elevated and could undermine the benefits of revenue‑cycle investments. Management explicitly warned that “denials and underpayments are still really high,” driven largely by Medicare Advantage, despite ongoing efforts to strengthen revenue cycle capabilities. If these issues persist or worsen, the anticipated gains from digital integration and appeals processes may not materialize, keeping EBITDA margins pressured. The market’s optimism about AI‑driven productivity could be overstated if revenue leakage continues to offset cost savings.
Seasonal volume volatility, while labeled temporal, could become a recurring drag if respiratory illness patterns shift or if extreme weather events increase in frequency. The Q1 respiratory‑related admissions fell 42% and ER visits dropped 32%, costing an estimated $180 million in EBITDA impact, with a winter storm further reducing admissions by 30 bps and ER visits by 50 bps. Management expects these effects to be confined to Q1, but any change in the timing or severity of flu seasons or winter storms could repeatedly disrupt volumes, especially given the company’s high fixed cost base. Investors may be underestimating the potential for these exogenous shocks to become a more persistent earnings headwind.

Exchange‑driven payer mix deterioration remains a material and underappreciated headwind that could erode profitability faster than anticipated. Exchange equivalent admissions fell 15% in the quarter, while uninsured equivalent admissions rose 16%, generating an estimated $150 million EBITDA impact in Q1 and a full‑year guidance range of $600‑$900 million. Management acknowledged that the shift from silver to bronze plans and rising patient cost‑share are increasing patient amounts due, which historically collect at lower rates than traditional managed care. If the exchange attrition accelerates or if Medicaid conversion slowdown persists, the uninsured burden could widen, pressuring bad‑debt reserves and offsetting gains from supplemental payments and cost‑savings initiatives.
Reliance on Medicaid supplemental payment programs introduces earnings volatility that may not be fully captured in current forecasts. While Q1 benefited from a $200 million net boost, the company revised its full‑year supplemental payment outlook to a potential decline of $50‑$250 million versus prior year, excluding any future grandfathered approvals. The sustainability of these programs hinges on state budget decisions and federal approval processes, which are inherently uncertain. A delay or denial of Florida’s pending program, or a rollback of existing programs in Georgia or Texas, could reverse the recent earnings boost and leave HCA more exposed to the underlying volume and payer mix pressures.
Operational challenges in specific markets, exemplified by North Carolina, reveal localized cost pressures that could scale if similar workforce shortages emerge elsewhere. HCA noted it is “a little bit behind our expectations in North Carolina on the bottom line” due to above‑expected demand requiring costly temporary labor to overcome a workforce deficit. If other regions experience comparable demand surges coupled with labor scarcity, the incremental cost burden could erode the modest salary and benefits margin improvements seen company‑wide. The market may view these as isolated issues, yet they signal a potential systemic risk to cost control in tight labor markets.
Denials and underpayments, particularly within Medicare Advantage, remain elevated and could undermine the benefits of revenue‑cycle investments. Management explicitly warned that “denials and underpayments are still really high,” driven largely by Medicare Advantage, despite ongoing efforts to strengthen revenue cycle capabilities. If these issues persist or worsen, the anticipated gains from digital integration and appeals processes may not materialize, keeping EBITDA margins pressured. The market’s optimism about AI‑driven productivity could be overstated if revenue leakage continues to offset cost savings.
Seasonal volume volatility, while labeled temporal, could become a recurring drag if respiratory illness patterns shift or if extreme weather events increase in frequency. The Q1 respiratory‑related admissions fell 42% and ER visits dropped 32%, costing an estimated $180 million in EBITDA impact, with a winter storm further reducing admissions by 30 bps and ER visits by 50 bps. Management expects these effects to be confined to Q1, but any change in the timing or severity of flu seasons or winter storms could repeatedly disrupt volumes, especially given the company’s high fixed cost base. Investors may be underestimating the potential for these exogenous shocks to become a more persistent earnings headwind.

Peer Comparison

Companies in the Medical Care Facilities

S.No.	Ticker	Company	Market Cap	P/E	P/S	Total Debt (Qtr)
1	HCA	HCA Healthcare, Inc.	87.94 Bn	11.25	1.15	48.02 Bn
2	CHE	Chemed Corp	18.08 Bn	51.68	7.12	0.09 Bn
3	THC	Tenet Healthcare Corp	16.59 Bn	9.74	0.77	13.21 Bn
4	DVA	Davita Inc.	15.37 Bn	14.02	1.10	10.63 Bn
5	EHC	Encompass Health Corp	10.07 Bn	654.20	1.66	2.57 Bn
6	ENSG	Ensign Group, Inc	9.52 Bn	27.18	1.81	0.14 Bn
7	UHS	Universal Health Services Inc	9.19 Bn	6.05	0.52	4.71 Bn
8	PACS	PACS Group, Inc.	6.96 Bn	28.55	1.28	0.05 Bn

Research Tools

Developers

About

Investment Thesis

Consolidation Items Breakdown of Revenue (2025)

Peer Comparison

Research Tools

Developers

About

Investment Thesis

Consolidation Items Breakdown of Revenue (2025)

Peer Comparison

Create an account

Sign In

Reset Password